Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer

View ORCID ProfileHai-ni Wen, Yi-xi Liu, Da Xu, Kai-jing Zhao, View ORCID ProfileZheng Jiao
doi: https://doi.org/10.1101/2020.08.23.20179655
Hai-ni Wen
1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, P.R.China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hai-ni Wen
Yi-xi Liu
1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, P.R.China
2Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P.R.China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Da Xu
3Department of Clinical Pharmacology, Jiangsu Hengrui Medicine Co. Ltd, Shanghai, P.R.China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-jing Zhao
3Department of Clinical Pharmacology, Jiangsu Hengrui Medicine Co. Ltd, Shanghai, P.R.China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Jiao
1Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, P.R.China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zheng Jiao
  • For correspondence: jiaozhen{at}online.sh.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Pyrotinib, a novel oral irreversible dual pan-ErbB tyrosine kinase inhibitor (TKI), has been approved in China for the treatment of HER2-positive advanced or metastatic breast cancer. This study aimed to conduct a population pharmacokinetics (PK) analysis of pyrotinib and to evaluate the impact of certain HER2-positive breast cancer patient characteristics on pyrotinib’s PK.

Method A total of 1152 samples, provided by 59 adult female patients from two phase I clinical trials, were analyzed by nonlinear mixed-effects modeling. Monte Carlo simulation was conducted to assess the impact of covariates following exposure to pyrotinib.

Results The PK of pyrotinib was adequately described by a one-compartment model with first-order absorption and elimination. Patient’s age and total protein levels can affect pyrotinib’s apparent volume of distribution, and concomitant use of montmorillonite powder had significant effects on the bioavailability of pyrotinib. No PK interactions were observed between capecitabine and pyrotinib.

Conclusion In this study, a population PK model of pyrotinib was developed to determine the influence of patient characteristics on the PK of pyrotinib. While patient age and total protein levels can significantly affect the apparent distribution volume of pyrotinib, the magnitude of the impact was limited, thus no dosage adjustment was recommended. Furthermore, concomitant use of montmorillonite powder for diarrhea can decrease the bioavailability of pyrotinib by 50.3%.

Competing Interest Statement

This study was funded by Jiangsu Hengrui Medicine Co. Ltd. Da Xu, Kai-jing Zhao are employees of Jiangsu Hengrui Medicine Co. Ltd.

Clinical Trial

NCT01937689;NCT02361112

Funding Statement

This study was funded by Jiangsu Hengrui Medicine Co. Ltd. Da Xu, Kai-jing Zhao are employees of Jiangsu Hengrui Medicine Co. Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Both studies were conducted in accordance with the principles of the Declaration of Helsinki (October 2013) and the International Conference on Harmonization Guidelines for Good Clinical Practice. Study protocols were approved by the ethics committee at each trial center. Informed consent was obtained from each participant included in each study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.

  • Abbreviations

    ALT
    alanine aminotransferase
    AST
    aspartate aminotransferase
    AUC
    concentration-time curve
    BMI
    body mass index
    BSV
    between-subject variability
    BW
    body weight
    CL/F
    apparent clearance
    CYP
    cytochrome P450
    CWRES
    conditional weighted residual error
    eGFR
    estimated glomerular filtration rate
    GOF
    goodness-of-fit
    HER
    human epidermal growth factor receptor
    ka
    absorption rate constant
    LLOQ
    lower limit of quantitation
    pcVPC
    prediction corrected visual prediction check
    popPK
    population PK
    PK
    pharmacokinetics
    RUV
    residual unexplained variability
    SCr
    serum creatinine
    TB
    total bilirubin
    TKI
    tyrosine kinase inhibitors
    TP
    total protein
    Vd/F
    apparent volume of distribution
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted August 25, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer
    Hai-ni Wen, Yi-xi Liu, Da Xu, Kai-jing Zhao, Zheng Jiao
    medRxiv 2020.08.23.20179655; doi: https://doi.org/10.1101/2020.08.23.20179655
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer
    Hai-ni Wen, Yi-xi Liu, Da Xu, Kai-jing Zhao, Zheng Jiao
    medRxiv 2020.08.23.20179655; doi: https://doi.org/10.1101/2020.08.23.20179655

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Pharmacology and Therapeutics
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)